Bio-Rad Laboratories Inc. Class A (NYSE: BIO) stock closed at 785.64 per share at the end of the most recent trading day (a 0.02% change compared to the prior day closing price) with a volume of 94.43K shares and market capitalization of 23.80B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class A CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class A stock is 56.12%, while year-to-date (YTD) performance is 34.77%. BIO stock has a five-year performance of 386.95%. Its 52-week range is between 490.73 and 832.7, which gives BIO stock a 52-week price range ratio of 90.27%

Bio-Rad Laboratories Inc. Class A currently has a PE ratio of 5.90, a price-to-book (PB) ratio of 2.02, a price-to-sale (PS) ratio of 6.71, a price to cashflow ratio of 34.50, a PEG ratio of 2.32, a ROA of 31.39%, a ROC of 40.75% and a ROE of 41.80%. The company’s profit margin is 84.36%, its EBITDA margin is 186.30%, and its revenue ttm is $2.88 Billion , which makes it $116.57 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.30 for the next earnings report. Bio-Rad Laboratories Inc. Class A’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class A is Strong Buy (1), with a target price of $843.33, which is +5.55% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class A stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class A has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.18, ATR14 : 16.66, CCI20 : -93.53, Chaikin Money Flow : 0.15, MACD : 6.23, Money Flow Index : 52.61, ROC : -4.16, RSI : 50.04, STOCH (14,3) : 19.71, STOCH RSI : 0.16, UO : 53.06, Williams %R : -80.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class A in the last 12-months were: Ajit Ramalingam (Option Excercise at a value of $0), Andrew J. Last (Option Excercise at a value of $598 480), Andrew J. Last (Sold 2 000 shares of value $1 626 203 ), Annette Tumolo (Option Excercise at a value of $191 184), Annette Tumolo (Sold 1 800 shares of value $1 244 413 ), Dara Wright (Option Excercise at a value of $0), Ilan Daskal (Option Excercise at a value of $716 898), Ilan Daskal (Sold 3 110 shares of value $2 397 778 ), Michael Crowley (Option Excercise at a value of $418 680), Michael Crowley (Sold 3 374 shares of value $2 481 966 ), Norman Schwartz (Option Excercise at a value of $3 702 220), Timothy S. Ernst (Option Excercise at a value of $63 728), Timothy S. Ernst (Sold 1 446 shares of value $965 649 )